---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-108422"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:11:20.693654+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Palvella Q2 net loss $9.5M; Phase 3 LM trial enrollment exceeded target by 25%

## Summary
- Phase 3 SELVA enrolled 51 subjects (target 40); top-line results expected Q1 2026.
- Cash $70.4M; expected to fund operations into second half of 2027.
- Net loss $9.5M ($0.86/share) vs $4.4M ($2.47); R&D and G&A up due to trial costs.
- Company plans to announce third QTORIN rapamycin indication and second platform candidate before year-end 2025.
- Appointed Ashley Kline as Chief Commercial Officer; added to Russell 2000/3000 indexes.

## SEC filing metadata
- accession: 0000950170-25-108422
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000095017025108422/0000950170-25-108422-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000095017025108422/pvla-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-108422
- JSON: https://secwatch.observer/filing/0000950170-25-108422.json
- Plain text: https://secwatch.observer/filing/0000950170-25-108422.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.